SHPH

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Shuttle Pharmaceuticals is a discovery and development-stage biopharmaceutical company focused on developing novel therapies to sensitize cancer cells to radiation therapy and protect normal tissues. The company's lead candidate, Ropidoxuridine, has received FDA approval for a Phase II clinical trial in glioblastoma patients. The company is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Liquidity Decline: Cash and cash equivalents decreased by approximately $1.9 million (87%) year-over-year, driven by operating losses and debt repayments. Working capital declined by 76% to $1.1 million.
• Operating Expenses: Total operating expenses decreased slightly by 5% to $2.9 million. Research and Development (R&D) expenses dropped 30% to $1.2 million as the company completed drug product manufacturing and awaited trial initiation. However, Legal and Professional fees increased 28% to $1.0 million due to public filing and financing requirements.
• Debt and Derivatives: The company settled $501,667 of convertible note principal in cash and issued 78,197 shares to settle accrued interest and principal. Interest expense decreased 30% to $0.9 million. The company recognized a $54,089 gain on the change in fair value of derivative liabilities, compared to a $1.7 million gain in the prior year.
• Stock Split: A 1-for-8 reverse stock split was effectuated on August 13, 2024, to meet Nasdaq listing requirements. All share data in this report has been retroactively adjusted.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Existing cash and marketable securities are insufficient to fund operations and clinical trials through that period.
• Financing Needs: The company is actively pursuing additional equity or debt financing. A planned $4.5 million rights offering has not yet been consummated as of the filing date. In August 2024, the company engaged an underwriter for a potential offering of up to $10.0 million.
• Debt Default and Waiver: In July 2024, the company notified its convertible note investor that an expected restatement of prior financials constituted an event of default. On August 6, 2024, the company paid $600,000 to the investor as collateral and received a waiver of the default.
• Clinical Progress: The Phase II trial for Ropidoxuridine in glioblastoma is on track. The company entered a work order with a CRO (Theradex Systems) in August 2024 to oversee the study, with a fee of approximately $2.3 million over 53 months.
• Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of June 30, 2024, citing material weaknesses in accounting policies, segregation of duties, and financial reporting oversight. A new CFO was hired in Q2 2024 to assist with remediation.

Investor Verification Checklist

• Capital Runway: Verify the status of the $4.5 million rights offering and the $10.0 million financing commitment to confirm if the company can fund operations beyond the current quarter.
• Debt Covenants: Monitor the terms of the Alto Convertible Note, specifically the $600,000 collateral payment and the conditions of the default waiver received in August 2024.
• Restatement Impact: Review the details of the expected restatement of 2022 and 2023 financial statements that triggered the debt default notice.
• Internal Controls: Assess the progress of remediation efforts regarding the identified material weaknesses in internal controls over financial reporting.
• Clinical Trial Costs: Confirm the funding source for the $2.3 million CRO contract signed in August 2024 for the Phase II trial.